Interim Report 1 January – 30 June 2024
· 45% sales growth despite transformation of sales organization · Additional SEK 12m in annual cost savings identified · Pause of EPIC-Knee trial to the advantage of other initiatives“We have started considerably faster in the US than what we have seen in any other market. For example, during the second quarter, the US market represents approx. 45% of the turnover in Germany, which is by far our largest market to date. In other words, we follow our strategy. We also see good opportunities to continue the beaten track at an ever-increasing speed. We will continue with our commercial